Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002225 | A Study of Efavirenz in Combination With Stavudine and Didanosine | PHASE2 | COMPLETED | 60 | — | — | - | - | Jun 24, 2005 | 5 | United States |
| NCT00002227 | A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs | PHASE2 | COMPLETED | 60 | — | — | - | - | Jun 24, 2005 | 8 | United States |
| Name | Type | Description |
|---|---|---|
| Efavirenz | DRUG | - |
| Stavudine | DRUG | - |
| Didanosine | DRUG | - |
| Lamivudine | DRUG | - |
Inclusion Criteria Patients must have: * Documented HIV infection with plasma HIV-RNA greater than or equal to 10,000 copies/ml. * A life expectancy of at least 12 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Current bilat...